Summary
This report presents findings on the adoption and retention of GLP-1 receptor agonists (RAs) and SGLT2 inhibitors (SGLT2-Is) among diabetes patients. It highlights the satisfaction levels of patients using various diabetes medications, specifically comparing newer treatments like Ozempic and Mounjaro to older options such as Trulicity and Invokana. The report indicates that a significant number of patients dissatisfied with older treatments have switched to newer therapies, reporting higher satisfaction rates. For instance, 80% of former Ozempic users who switched to Mounjaro reported satisfaction compared to only 46% who remained on Ozempic. Additionally, the report notes that injection aversion is a barrier for many patients, suggesting a potential market for oral formulations of GLP-1 RAs. It also examines the competitive dynamics among SGLT2-Is, revealing that Invokana users experience higher attrition rates compared to those using Jardiance and Farxiga. The findings underscore the importance of weight loss as a factor influencing patient satisfaction and retention.
